Search

Guttate psoriasis (GP) is a variant of psoriasis characterized by scattered "drop-like" papules and plaques, accounting for up to a quarter of psoriasis cases. Although GP can clear within 3 to 4 months, up to 39% of cases may progress to chronic plaque psoriasis. Currently, there is a paucity of literature investigating the efficacy of different treatment modalities. This systematic review aims to synthesize all available data on GP treatment efficacy. A literature search was conducted using Medline, Embase, Web of Science, and CINAHL with no date limits. A total of 75 studies satisfied eligibility criteria and were analyzed. Most studies were case reports, series, or retrospective studies. Only 5 randomized controlled trials (RCTs) were identified. For topical treatments, corticosteroids and calcipotriol creams had the most evidence for efficacy. Four categories of systemic therapies were identified: traditional immunosuppressants, antibiotics, retinoids, and biologics. Evidence regarding antibiotic therapy suggests minimal connection between underlying infection resolution and GP lesion remission. Phototherapy had the most robust evidence, with narrowband ultraviolet B (UVB) being the most effective. Our findings are limited by high heterogeneity in study design and high risk of bias. Based on our review, we propose the following treatment algorithm. As first-line therapy, we recommend topical corticosteroids and calcipotriol cream, in combination with phototherapy. As supportive therapy, we recommend antibiotics if applicable. For second-line therapy, we recommend methotrexate or cyclosporine. For severe and refractory GP, biologics can be used as third-line treatment. RCTs are needed to provide higher quality evidence to create standardized treatment recommendations. [ABSTRACT FROM AUTHOR]

This article is a systematic review of the joint-related adverse effects (JRAEs) associated with the use of dupilumab, a medication used to treat atopic dermatitis. The review found that JRAEs, including joint stiffness, arthritis, and inflammatory arthropathies, have been increasingly reported in patients taking dupilumab. The incidence of JRAEs ranged from 0.2% to 10%, and treatment strategies included continuing or discontinuing dupilumab, starting adjuvant treatments, and switching to other systemic therapies. However, the precise incidence and causal relationship between JRAEs and dupilumab remain unclear, and further research is needed to better understand and categorize these adverse events. [Extracted from the article]